The role of heme oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and reperfusion injury

Kidney International

Volumn 70, Issue 10, 2006, Pages 1742-1749

  Goncalves G M ^a   Cenedeze, M A ^a   Feitoza, C Q ^a   Wang, P M H ^a   Bertocchi, A P F ^a   Damiao M J ^a   Pinheiro, H S ^b   Teixeira, V P Antunes ^c   Dos Reis, M A ^c   Pacheco Silva, A ^a   Camara N O S ^a,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^c FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Heme oxygenase 1; Ischemia and reperfusion injury; Rapamycin

Indexed keywords

HEME OXYGENASE 1; PORPHYRIN COBALT; PROTOPORPHYRIN; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME INDUCTION; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; TISSUE REGENERATION; UPREGULATION;

ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME OXYGENASE-1; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; PROTOPORPHYRINS; REPERFUSION INJURY; SIROLIMUS;

EID: 33750587035     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001893     Document Type: Article

References (46)

1. Nankivell BJ, Borrows BJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
2. Nankivell BJ, Borrows RJ, Fung CL et al. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434-441.
3. Azuma H, Nadeau K, Takada M et al. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation 1997; 64: 190-197.
4. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387-397.
5. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831-1840.
6. Kieran NE, Rabb H. Immune responses in kidney preservation and reperfusion injury. J Investig Med 2004; 52: 310-314.
7. Versteilen AM, Di Maggio F, Leemreis JR et al. Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs 2004; 27: 1019-1029.
8. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814-1827.
9. Ysebaert DK, De Greef KE, De Beuf A et al. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int 2004; 66: 491-496.
10. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004; 66: 500-506.
11. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313-318.
12. Burne-Taney MJ, Yokota-Ikeda N, Rabb H. Effects of combined T- and B-cell deficiency on murine ischemia reperfusion injury. Am J Transplant 2005; 5: 1186-1193.
13. Yakupoglu YK, Kahan BD. Sirolimus: a current perspective. Exp Clin Transplant 2003; 1: 8-18.
14. Fervenza FC, Fitzpatrick PM, Mertz J et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19: 1288-1292.
15. Boratynska M, Banasik M, Patrzalek D et al. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients. Transplant Proc 2005; 37: 839-842.
16. Simon JF, Swanson SJ, Agodoa LY et al. Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States. Am J Nephrol 2004; 24: 393-401.
17. McTaggart RA, Gottlieb D, Brooks J et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416-423.
18. Smith KD, Wrenshall LE, Nicosia RF et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037-1045.
19. Lieberthal W, Fuhro R, Andry CC et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693-F706.
20. Camara NO, Soares MP. Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic Biol Med 2005; 38: 426-435.
21. Soares MP, Lin Y, Anrather J et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998; 4: 1073-1077.
22. Vera T, Henegar JR, Drummond HA et al. Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. J Am Soc Nephrol 2005; 16: 950-958.
23. Tsuchihashi S, Fondevila C, Kupiec-Weglinski JW. Heme oxygenase system in ischemia and reperfusion injury. Ann Transplant 2004; 9: 84-87.
24. Vanrenterghem Y, van Hooff JP, Squifflet JP et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5: 87-95.
25. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
26. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
27. Ozaki KS, Camara NO, Galante NZ et al. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int Immunopharmacol 2005; 5: 103-106.
28. Loverre A, Ditonno P, Crovace A et al. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J Am Soc Nephrol 2004; 15: 2675-2686.
29. Pallet N, Thervet E, Le Corre D et al. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int 2005; 67: 2422-2433.
30. Puglisi RN, Strande L, Santos M et al. Beneficial effects of cyclosporine and rapamycin in small bowel ischemic injury. J Surg Res 1996; 65: 115-118.
31. Inman SR, Davis NA, Olson KM et al. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury. Urology 2003; 62: 750-754.
32. Stallone G, Di Paolo S, Schena A et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228-233.
33. McTaggart RA, Tomlanovich S, Bostrom A et al. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004; 78: 475-480.
34. Tsuchihashi S, Fondevila C, Kupiec-Weglinski JW. Heme oxygenase system in ischemia and reperfusion injury. Ann Transplant 2004; 9: 84-87.
35. Takahashi T, Morita K, Akagi R, Sassa S. Protective role of heme oxygenase-1 in renal ischemia. Antioxid Redox Signal 2004; 6: 867-877.
36. Akamatsu Y, Haga M, Tyagi S et al. Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemia reperfusion injury. FASEB J 2004; 18: 771-772.
37. Yamashita K, McDaid J, Ollinger R et al. Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J 2004; 18: 765-767.
38. Berberat PO, Katori M, Kaczmarek E et al. Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J 2003; 17: 1724-1726.
39. Visner GA, Lu F, Zhou H et al. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin. Circulation 2003; 107: 911-916.
40. Baan C, Peeters A, Lemos F et al. Fundamental role for HO-1 in the self-protection of renal allografts. Am J Transplant 2004; 4: 811-818.
41. Kis A, Yellon DM, Baxter GF. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 2003; 35: 1063-1071.
42. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15: 69-75.
43. Hausenloy D, Mocanu M, Yellon D. Cross-talk between the survival kinases during reperfusion in ischaemic preconditioning. Cardiovasc J S Afr 2004; 15(4 Suppl 1): S11.
44. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-460.
45. Yang XM, Krieg T, Cui L et al. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 2004; 36: 411-421.
46. Kelly KJ, Williams Jr WW, Colvin RB, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994; 91: 812-816.